The mad rush for safe and effective obesity drugs has winners—including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy—and ...

Vanda claims that two generics to its sleep disorder drug Hetlioz were approved despite inadequate data and is requesting ...

The platform strategy of using one molecule to target an underlying biological pathway to address many different diseases can ...

There’s still much more to come from the White House on tariffs, but the European Union has now reached a trade agreement ...

Drugs are being invented and manufactured right here in the U.S. by Americans, for Americans. So why doesn’t the industry ...

The FDA has identified critical lapses at a production facility operated by Novo Nordisk that is used by several drugmakers, ...

Krystal Biotech's decision follows the FDA’s rejection last month of Replimune’s RP1, which works similarly to Krystal ...

With results from highly anticipated trials of Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 “underwhelming” ...

Dawnzera is the first and so far only RNA-targeting therapy approved as a prophylactic treatment for hereditary angioedema ...

The FDA recommends that companies use overall survival as a primary endpoint for clinical trials where feasible. The new ...

Viking Therapeutics’ VK2735 achieves a 10.9% placebo-adjusted weight loss at 13 weeks, but a less than ideal safety profile ...

While it’s impossible to make apples-to-apples comparisons of the many obesity candidates with so many differences across ...